Anti-oncogenic activity of novel compounds and reference drugs <i>in vitro</i>. IGROV1 cells were treated with a series of FLT3/TAF1 compounds and cell viability was determined using a Cell-titer Glo assay, while cell toxicity was determined using a

(A) Compound activity in IGROV1 cells at 0.01-30 µM (n ≥ 3). (B) pIC₅₀ and IC₅₀ values of FLT3/TAF1 inhibitors. Dots represent independent experiments (n = 3) and mean ± SEM is shown. Both single FLT3 inhibitors (3i-1244, 3i-1245, 3i-1247) and dual FLT3/TAF1 inhibitors (3i-1103, 3i-1246, 3i-1248) were used for experiments. Compounds for which IC₅₀ values could not be generated for three experiments or which were determined to be greater than the maximal tested concentration (30 µM) are listed as n.d. (not determined). (PDF)